Shots: 

• ImmuNext to receive $40M upfront- $565M as development & commercialization milestones and royalties on sales of products. Lilly to get an exclusive WW licence to develop & commercialize novel immuno-therapies 
• Eli Lilly and ImmuNext plan to build a 3yrs. research collaboration supporting the development of preclinical targets for autoimmune diseases by regulating immune cell metabolism
• Immunomodulators are molecules that promote or suppress immune responses to restore immune homeostasis and cure disease related to autoimmunity- cancer- transplantation rejection- and infectious disease

  Ref: Eli lilly | Image: Eli Lilly